Simplifying treatment for children with ALL

Lancet

Volumn 369, Issue 9556, 2007, Pages 82-83

  Saha, Vaskar ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; ASPARAGINASE; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; STEROID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AVASCULAR NECROSIS; BEHAVIOR DISORDER; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL TRIAL; HUMAN; MORBIDITY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 33846063416     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60043-9     Document Type: Note

References (12)

1. Conter V., Grazia Valsecchi M., Silvestri D., et al. Intensification of continuation therapy with vincristine-dexamethasone pulses does not affect outcome of intermediate risk childhood acute lymphoblastic leukaemia treated with BFM protocols: results of the I-BFM-SG ALL IR 95 study. Lancet 369 (2007) 123-131
2. Schrappe M., Camitta B., Pui C., et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 14 (2000) 2193-2194
3. Improvement in treatment for children with acute lymphoblastic leukaemia. The Medical Research Council UKALL trials, 1972-84. Report to the Council by the Working Party on Leukaemia in Childhood. Lancet 327 (1986) 408-411
4. Eden O., Harrison G., Richards S., et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 14 (2000) 2307-2320
5. Mitchell C., Richards S., Kinsey S., Lilleyman J., Vora A., and Eden T. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 (2005) 734-745
6. Bostrom B., Sensel M., Sather H., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 (2003) 3809-3817
7. Pui C., and Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
8. Tubergen D., Gilchrist G., O'Brien R., et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 11 (1993) 527-537
9. Roy A., Bradburn M., Moorman A., et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 129 (2005) 35-44
10. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet 347 (1996) 1783-1788
11. Arico M., Conter V., Valsecchi M., et al. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica 90 (2005) 1186-1191
12. Lange B., Bostrom B., Cherlow J., et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99 (2002) 825-833